An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy

The study was to compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in Chinese men naοve to phosphodiesterase 5 (PDE5) inhibitor therapies. This multicenter, randomized, open-label, crossover study evaluate...

Full description

Bibliographic Details
Main Authors:	Wen-Jun Bai, Hong-Jun Li, Yu-Tian Dai, Xue-You He, Yi-Ran Huang, Ji-Hong Liu, Sebastian Sorsaburu, Chen Ji, Jian-Jun Jin, Xiao-Feng Wang
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-02-01
Series:	Asian Journal of Andrology
Subjects:	erectile dysfunction; patient preference; phosphodiesterase 5 inhibitors
Online Access:	http://www.ajandrology.com/article.asp?issn=1008-682X;year=2015;volume=17;issue=1;spage=61;epage=67;aulast=Bai

Similar Items

Effect of sildenafil citrate on the cardiovascular system
by: K. Shinlapawittayatorn, et al.
Published: (2005-09-01)

Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction
by: Moschos MM, et al.
Published: (2016-10-01)

PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE
by: M. N. Mamedov, et al.
Published: (2016-01-01)

Endothelial Dysfunction, Erectile Dysfunction and Phosphodiesterase 5 Inhibitors. An Update of the Current Data and Future Perspectives
by: Angelis Konstantinopoulos, et al.
Published: (2007-01-01)

Exercise training improves erectile dysfunction (ED) in patients with metabolic syndrome on phosphodiesterase-5 (PDE-5) inhibitors
by: Luigi Maresca, et al.
Published: (2013-12-01)

A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction
by: Jin-Qiu Yuan, et al.
Published: (2016-01-01)

Erectile dysfunction in patients taking psychotropic drugs and treated with phosphodiesterase-5 inhibitors
by: Rossella Mazzilli, et al.
Published: (2018-03-01)

Phosphodiesterase-5 inhibitors for erectile dysfunction in patients with diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
by: Yatan Pal Singh Balhara, et al.
Published: (2015-01-01)

Safety and efficacy of sildenafil in Brazilian men with erectile dysfunction secondary to spinal cord injury
by: Carlos Eurico Dornelles Cairoli, et al.
Published: (2008-03-01)

Influence of regular use of vardenafil on endothelial and erectile functions in patients with arteriogenic erectile dysfunction
by: Safar Israilovich Gamidov, et al.
Published: (2009-10-01)

The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews
by: Nikolaos Pyrgidis, et al.
Published: (2021-09-01)

Obesity and Erectile Dysfunction: From Bench to Clinical Implication
by: Ki Hak Moon, et al.
Published: (2019-05-01)

The blue pill (sildenafil) and its descendants: an overview
by: Krzanowski Tomasz, et al.
Published: (2017-09-01)

Tadalafil as New Treatment in Erectile Dysfunction: A Review
by: Bagus Komang Satriyasa
Published: (2017-01-01)

Tadalafil once daily and intralesional verapamil injection: A new therapeutic direction in Peyronie′s disease
by: Lucio Dell′Atti
Published: (2015-01-01)

Audiovisual Sexual Stimulation and RigiScan Test for the Diagnosis of Erectile Dysfunction
by: Tao Wang, et al.
Published: (2018-01-01)

Erectile dysfunction in diabetes mellitus: A review
by: Deepak K Jumani, et al.
Published: (2020-01-01)

Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic
by: Müslim Dogan Değer, et al.
Published: (2021-10-01)

Diagnosis of erectile dysfunction can be used to improve screening for Type 2 diabetes mellitus
by: Carrillo-Larco, Rodrigo M., et al.
Published: (2018)

Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial
by: Hui Jiang, et al.
Published: (2018-01-01)

Postprostatectomy Erectile Dysfunction: A Review
by: Paolo Capogrosso, et al.
Published: (2016-08-01)

Pharmacotherapy of erectile dysfunction: Current standards
by: Kew-Kim Chew
Published: (2006-01-01)

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study
by: Seung-Hun Song, et al.
Published: (2021-05-01)

Effect of phosphodiesterase type 5 inhibitors on sperm motility and acrosome reaction: An in vitro study
by: Seung-Hun Song, et al.
Published: (2021-05-01)

Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus
by: Popović Srđan, et al.
Published: (2007-01-01)

Molecular and Histologic Evidence of Novel Erectile Dysfunction Rat Model as an Aging Atherosclerosis Model: A Preliminary Study
by: Jae Heon Kim, et al.
Published: (2020-07-01)

Promising role of medicinal plants in the regulation and management of male erectile dysfunction
by: Nelisiwe Prenate Masuku, et al.
Published: (2020-10-01)

EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil
by: Giovanni Corona, MD, PhD, et al.
Published: (2018-03-01)

A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation
by: Vincenzo Mirone, et al.
Published: (2021-06-01)

Treatment of Erectile Dysfunction in Type 2 Diabetic Men
by: V.Ye. Luchytskyi
Published: (2015-11-01)

Peyronie′s disease and erectile dysfunction: Current understanding and future direction
by: Laurence A Levine
Published: (2006-01-01)

Effects of sildenafil on autonomic nervous function during sleep in obstructive sleep apnea
by: Christiane Neves, et al.
Published: (2010-01-01)

Efficacy and safety of short- and long-term, regular and on-demand regimens of phosphodiesterase type 5 inhibitors in treating erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis
by: Tian D, et al.
Published: (2017-02-01)

Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction
by: Connie C. J. Louizos, et al.
Published: (2015-11-01)

A Multicenter, Randomized, Open-Labeled, Parallel Group Trial of Sildenafil in Alcohol-Associated Erectile Dysfunction: The Impact on Psychosocial Outcomes
by: Alexander Grinshpoon, et al.
Published: (2009-09-01)

Effect of sildenafil in cavernous arteries of patients with erectile dysfunction
by: Joaquim A Claro, et al.
Published: (2003-08-01)

Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism
by: E B Mazo, et al.
Published: (2008-12-01)

Sildenafil or Vardenafil Nonresponders’ Erectile Response to Tadalafil
by: Berat Cem Ozgur, et al.
Published: (2009-12-01)

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome
by: Ridwan Shabsigh, MD, FACS, et al.
Published: (2016-09-01)

Hyperprolactinemia contributes to reproductive deficit in male rats chronically administered PDE5 inhibitors (sildenafil and tadalafil) and opioid (tramadol)
by: V.U. Nna, et al.
Published: (2016-09-01)